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ABSTRACT
We investigated the mechanisms responsible for the widespread refrac-
toriness to chemotherapeutic drugs observed in thyroid cancers. We show
that malignant epithelial cells from papillary, follicular, and anaplastic
thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous
expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to
prevent chemotherapeutic drug-induced cytotoxicity. All of the histologi-
cal thyroid cancer variants examined produced interleukin-4 (IL-4) and
interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and pro-
tected thyroid cells from chemotherapeutic agents. Exposure to neutral-
izing antibodies against IL-4 and IL-10 resulted in down-modulation of
Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer
cells, and sensitization of the residual tumor population to cytotoxic
drug-induced apoptosis. In conclusion, autocrine production of IL-4 and
IL-10 promotes thyroid tumor cell progression and resistance to chemo-
therapy through the up-regulation of antiapoptotic proteins. Thus, IL-4
and IL-10 may represent new therapeutic targets for the treatment of
thyroid cancer.
INTRODUCTION
Thyroid cancer is the most common endocrine malignancy and is
responsible for about 60% of deaths secondary to endocrine cancer (1,
2). Three major types of malignant tumors originate from the thyroid
epithelium. The more differentiated PTCs and FTCs account for most
of the malignant tumors, whereas the UTCs are extremely rare (3).
Clinical trials with chemotherapeutic drugs have produced only rare
and limited positive responses in thyroid cancer (4–6). The expres-
sion of the multidrug resistance gene is altered in a small subset of
thyroid carcinomas (7–9), but the molecular bases implicated in the
failure of chemotherapy-based regimens have not been defined in the
vast majority of thyroid carcinomas.
Antineoplastic drugs are a class of cytotoxic compounds that se-
lectively target proliferating cells by interfering with DNA replication
or transcription (10, 11). They activate the intrinsic apoptotic pathway
that involves the release from mitochondria of death factors such as
cytochrome c and Apaf-1, resulting in the formation of a holoenzyme
complex (called the apoptosome) that triggers activation of caspase 9
and executioner caspases responsible for completion of the death
program (12, 13). A network of cellular proteins influences the
ultimate outcome of drug-induced damage (14). The relative levels
and competing dimerization between Bcl-2 family members regulate
cytochrome c release from mitochondria, thus determining cell sus-
ceptibility to apoptotic signals (15). High expression of the antiapo-
ptotic members of the Bcl-2 family is commonly found in human
cancers and contributes to both neoplastic cell expansion and resist-
ance to the therapeutic action of cytotoxic drugs (16, 17). Accord-
ingly, several studies have shown that functional blockade of Bcl-2 or
Bcl-xL can either restore the apoptotic process in tumor cells or
sensitize these tumors to chemotherapies and radiotherapies (18–21).
Thus, up-regulation of antiapoptotic Bcl-2 family members promotes
cancer growth and impairs the effectiveness of therapeutic procedures.
As suggested by experimental evidences on cell lines and primary
cells (22), the considerable resistance of thyroid tumors to chemo-
therapeutic drugs may result from altered expression of antiapoptotic
proteins.
Cytokines promote the expression of a variety of genes involved in
the survival or death of different target cells (23–26). Three function-
ally distinct subsets of T-helper cells have been characterized on the
basis of cytokine production (27). TH1 cells secrete IFN- and other
cytokines associated with inflammation and cell-mediated immune
responses. In contrast, TH2 cells promote the humoral response and
produce IL-4, IL-5, and IL-10, whereas TH3 cells inhibit the immune
response through the release of IL-10 and transforming growth factor
-1 (27–29). We recently demonstrated that cytokines released by
T-helper lymphocytes control autoimmune thyroid destruction
through the modulation of proapoptotic and antiapoptotic proteins in
target cells. IFN- contributes to autoimmune thyrocyte destruction
through the up-regulation of CD95, caspase-3, and caspase-8, whereas
IL-4 and IL-10 promote thyrocyte survival during nondestructive
autoimmunity through the up-regulation of cellular FLICE inhibitory
protein (cFLIP) and Bcl-xL (30, 31).
We speculated that the modulation of apoptosis-related proteins by
T-helper cytokines was not restricted to normal thyrocytes but could
be involved in the survival of thyroid cancer cells. We, therefore,
investigated the presence of IL-4 and IL-10 in the thyroid cancer
microenvironment and whether they were responsible for refractori-
ness to chemotherapy.
MATERIALS AND METHODS
Specimens. Thyroid tissues from patients affected by PTC (n  8; age,
45 5 years), FTC (n 8; age, 48 3 years), and UTC (n 4; age, 67 4.5
years) were obtained at thyroidectomy, in accordance with the ethical stand-
ards of the Institutional Responsible Committee on human experimentation.
Control thyroid specimens were obtained from the uninvolved, controlateral
lobes of tumor glands or from nontoxic goiter glands (n  10; age, 56  10
years). Histological diagnosis was based on the identification of papillary
elements, on the behavioral characteristics of carcinoma cells (vascular and
capsular invasion), and on nuclear atypia (shape and chromatin pattern).
Transgenic mouse hearts expressing human Bcl-xL, provided by G. Condorelli
(Thomas Jefferson University, Philadelphia, PA), and HL-60 cells were used
as positive controls.
Thyroid Cell Purification, Culture, and Cell Death Quantitation. Tis-
sues from normal, PTC, FTC, and UTC thyroids were digested for 2 h with
collagenase (1.5 mg/ml; Life Technologies, Inc., Grand Island, NY) and
hyaluronidase (20 g/ml; Sigma Chemical Co., St. Louis, MO) in DMEM
(30). Thyrocytes were purified from the digested tissues by hematopoietic cell
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depletion with anti-CD45-coupled beads (Dynal, Wirral Merseyside, United
Kingdom) and 12 h of flask adherence, which allowed removal of other cells.
After an additional 12 h of culture, thyroid cells were allowed to grow in
monolayer for immunocytochemistry or were detached with trypsinEDTA
after exposure to cytokines or chemotherapeutic agents for functional and
protein analyses. Thyrocytes were cultured in standard DMEM with 10%
heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, United
Kingdom) in the presence or absence of human recombinant IL-4 (20 ng/ml),
IL-10 (40 ng/ml), or IFN- (1000 IU/ml; Euroclone, Paignton, United King-
dom) with or without cysplatinum (300 ng/ml), doxorubicin (5 M), or Taxol
(5 M; Sigma Chemical Co.). Autocrine release of IL-4 and IL-10 was
neutralized, exposing thyrocytes for 48 h with 10 g/ml Abs specific to IL-4
(3007, mouse IgG1; R&D Systems, Inc., Minneapolis, MN) or IL-10 (23738,
mouse IgG2b; R&D Systems).
Death of normal and neoplastic thyrocytes was evaluated by DNA staining,
followed by flow cytometry analysis as described previously (30). Alterna-
tively, freshly purified thyrocytes were plated in flat-bottomed 96-well plates
in triplicate at 20,000 cells/well and cultured. The number of viable cells was
detected using CellTiter Aqueous Assay kit (Promega Corp., Madison, WI).
Immunostaining Procedure. Immunohistochemical stainings were per-
formed on 5-m-thick paraffin-embedded sections or in thyrocyte monolayers.
Slides were incubated for 10 min in TBS containing 3% BSA to block
unspecific staining. After elimination of excess serum, specimens were ex-
posed for 1 h to specific Abs against Bcl-xL (H-5, mouse IgG1; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), Bcl-2 (124, mouse IgG1; DAKO Corp.,
Carpinteria CA), IL-4 (B-S4 mouse IgG1; Caltag Laboratories, Burlingame,
CA), IL-10 (B-N10 mouse IgG2a; Caltag Laboratories), IFN- (B27, mouse
IgG1; Caltag Laboratories), human cytokeratin (AE1/AE3, mouse IgG1;
DAKO Corp.), or isotype-matched controls at appropriate dilutions. After two
washes in TBS, sections were treated with biotinylated antirabbit or antimouse
immunoglobulins, washed in TBS, and incubated in streptavidin peroxidase
(DAKO LSAB 2 kit; DAKO Corp.). Staining was detected using 3-amino-9-
ethylcarbazole as a colorimetric substrate. Counterstaining of cells and tissue
sections was performed using aqueous hematoxylin.
Fig. 1. Resistance to apoptotic cell death induced by chemo-
therapeutic drugs in thyroid cancer cells. Percentage of cell
death in freshly purified thyroid epithelial cells from control,
PTC, FTC, and UTC glands exposed for 6, 12, and 24 h to
cisplatinum (300 ng/ml), doxorubicin (5 M), and taxol (5 M).
Data are mean  SD of four independent experiments, each
performed with cells from different donors.
Fig. 2. Expression of antiapoptotic molecules in
thyroid cancer. a and b, immunohistochemical
analysis of Bcl-xL and Bcl-2 on paraffin sections of
control thyroid gland, PTC, FTC, and UTC re-
vealed by 3-amino-9-ethylcarbazole (red staining).
Black arrows indicate Bcl-2 expression on less
differentiated areas of UTC. c and d, immunoblot
analysis of Bcl-xL and Bcl-2 in freshly purified
thyroid cell lysates from control, PTC, FTC, and
UTC thyroids. Bcl-xL transgenic hearts and HL-60
cells were used as positive controls. Loading con-
trols were performed by detecting -actin in the
same membrane blot. One representative experi-
ment of four performed with cells from different
donors is shown.
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Protein Isolation and Western Blotting. Cell pellets were resuspended in
ice-cold NP40 lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
EGTA, and 1% NP40] containing 1 mM phenylmethylsulfonyl fluoride, leu-
peptin (1 g/ml), pepstatin (1 g/ml), and aprotinin (1 g/ml). Lysates (30
g/lane) were fractioned on SDS-polyacrylamide gels and blotted to nitrocel-
lulose. Membranes were blocked for 1 h with nonfat dry milk in TBS
containing 0.05% Tween 20 and successively incubated for 3 h with Abs
specific to actin (Ab-1, mouse IgM; Calbiochem, Darmstadt, Germany), Bcl-2
(124, mouse IgG1; Upstate Biotechnology Inc.), Bcl-xL (H-5, mouse IgG1;
Santa Cruz Biotechnology), IL-4 (3007, mouse IgG1; R&D Systems), IL-10
(23738, mouse IgG2b; R&D Systems), or IFN- (25723, mouse IgG2b; R&D
Systems). After washing, the blots were incubated for 1 h with horseradish
peroxidase-conjugated antimouse Ab (Amersham) and visualized using an
enhanced chemiluminescence detection system (SuperSignal West Dura Ex-
tended duration Substrate; Pierce Chemical Co., Rockford, IL). Recombinant
IL-4, IL-10, and IFN- (Euroclone) were used as positive controls.
Production of Retroviral Particles and Infection of Thyrocytes. Bcl-2
and Bcl-xL cDNAs were cloned into the PINCO vector (32). The amphotropic
Phoenix packaging cell line was transiently transfected with PINCO using the
calcium-phosphate/chloroquine method. Infection was performed by culturing
5  105 thyrocytes in 1 ml of 0.45 mM filtered supernatant containing viral
particles. Then, cells were centrifuged for 45 min at 1800 rpm and placed back
in the CO2 incubator for 2 h. Three infection cycles were performed before the
thyrocytes were placed back in supplemented medium. Sorted and enriched
positive cells were plated and exposed to cisplatinum, doxorubicin, and taxol
for evaluation of cell death.
RESULTS
Thyroid Cancer Cells Are Resistant to Chemotherapy-induced
Cell Death. To investigate the sensitivity of thyroid carcinomas to
conventional chemotherapeutic drugs, we measured the viability of
freshly purified thyroid cells exposed to cisplatinum (300 ng/ml),
doxorubicin (5 M), and taxol (5 M) using dosages equivalent to
those reached during cancer treatment. In line with the modest effi-
cacy reported in clinical trials, primary neoplastic cells from all
histological variants of thyroid carcinomas showed a scarce sensitivity
to the different drugs used (Fig. 1). Thus, the inefficacy of chemo-
therapy likely results from direct resistance of thyroid cancer cells to
cytotoxic drugs.
Thyroid Cancer Cells Express Bcl-2 and Bcl-xL. Refractoriness
to chemotherapy may result from the activity of antiapoptotic genes.
Therefore, we evaluated the expression of a number of relevant
antiapoptotic proteins. We found by immunohistochemistry that thy-
roid carcinoma cells were strongly immunoreactive to Bcl-2 and
Bcl-xL (Fig. 2, a and b). To determine more accurately the difference
between normal and malignant thyroid cells, freshly purified control
and neoplastic cells were lysed and analyzed by immunoblot. We
found that Bcl-xL was weakly expressed in control cells but 4- to
5-fold up-regulated in all of the histological cancer variants, whereas
Bcl-2 was found 3-fold higher in FTC cells and 2-fold higher in
PTC and UTC cells (Fig. 2, c and d). The levels of Bcl-2 in UTC were
not homogeneous, because the more differentiated areas expressed
higher amounts of this antiapoptotic protein. The ability of Bcl-xL and
Bcl-2 overexpression to protect some cell types against the cytotoxic
effect of chemotherapeutic drugs suggests a potential role of these
proteins in thyroid cancer resistance to drug-induced cytotoxicity.
Exogenous Bcl-2 and Bcl-xL Protect Thyrocytes from Cell
Death Induced by Chemotherapeutic Agents. To prove that Bcl-xL
and Bcl-2 up-regulation protects thyrocytes from apoptosis induced
by chemotherapeutic drugs and may be responsible for cancer cell
survival, control thyrocytes were transduced with a retroviral vector
(PINCO) carrying the green fluorescent protein as a gene reporter.
After infection, thyrocytes transduced with empty vector, Bcl-xL, and
Bcl-2 were sorted by flow cytometry and exposed to cisplatinum,
doxorubicin, and taxol to evaluate the extent of chemotherapy-
induced apoptosis. The infections were monitored by immunoblot
analysis to confirm the efficiency of gene delivery (Fig. 3a). Thyro-
cytes transduced with either Bcl-xL or Bcl-2 were almost completely
protected from the cytotoxic effects of the chemotherapeutic agents
(Fig. 3, b and c), indicating that overexpression of either of the two
genes is sufficient to prevent thyroid cell death. Thus, Bcl-xL and
Bcl-2 represent likely candidates for mediating refractoriness of thy-
roid cancer cells to chemotherapy.
Autocrine Production of IL-4 and IL-10 in Thyroid Cancer
Cells. To investigate whether the tumor microenvironment influences
thyroid cancer cell phenotype and function, we evaluated the presence
of cytokines previously found to modulate thyrocyte susceptibility to
Fig. 3. Protection from chemotherapy-induced cell death in thyrocytes transduced with
Bcl-xL and Bcl-2. a, immunoblot analysis of Bcl-xL and Bcl-2 expression on flow
cytometry-sorted thyrocytes transduced with empty vector (Vector), Bcl-xL, and Bcl-2.
Loading control was assessed by -actin staining. b, percentage of viable control thyro-
cytes transduced as in a after exposure for 12 h to chemotherapeutic drugs. c, immuno-
fluorescence analysis of green fluorescent protein-positive cells treated as in b and stained
with ethidium bromide. Data are representative of three independent experiments.
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apoptosis. All of the histological variants expressed increased immu-
noreactivity to IL-4 and IL-10, whereas IFN- was not detectable
(Fig. 4a). Interestingly, the reactivity against TH2 cytokines localized
to thyroid follicles, suggesting that neoplastic thyroid cells were the
source of production for both IL-4 and IL-10 (Fig. 4a). To rule out the
possibility that the reactivity observed in tumor cells was exclusively
caused by the release of TH2 cytokines by infiltrating T cells, freshly
purified thyroid cancer cells were analyzed by immunocytochemistry
and immunoblot. As observed with immunohistochemistry, purified
thyroid cancer cells were intensely reactive to both IL-4 and IL-10,
whereas IFN- was not present (Fig. 4, b and c), demonstrating that
malignant thyroid cells produce considerable amounts of antiapoptotic
TH2 cytokines.
IL-4 and IL-10 Protect Thyrocytes from Cell Death Induced by
Chemotherapeutic Agents. We next investigated whether IL-4 and
IL-10 modulate sensitivity to chemotherapy-induced apoptosis and
expression of antiapoptotic proteins in thyroid cells. Interestingly,
both IL-4 and IL-10 prevented death of normal thyrocytes exposed to
cisplatinum, doxorubicin, and taxol (Fig. 5a), suggesting that auto-
crine production of these cytokines in thyroid cancer cells is respon-
sible for refractoriness to chemotherapy. Furthermore, both IL-4 and
IL-10 up-regulated Bcl-xL and Bcl-2 after 48 h of culture (Fig. 5b),
whereas IFN- was not effective, indicating that autocrine release of
IL-4 and IL-10 results in up-regulation of antiapoptotic proteins and
subsequent protection of thyroid cancer cells from chemotherapy.
Neutralization of IL-4 and IL-10 Promotes Thyroid Cancer
Cells Apoptosis. To formally prove that the production of IL-4 and
IL-10 inside the tumor is responsible for up-regulation of antiapo-
ptotic proteins in thyroid cancer cells, we treated follicular carcinoma
cells for 2 days with IL-4- and IL-10-neutralizing Abs and then
measured Bcl-xL and Bcl-2 expression. The levels of these proteins
decreased significantly in thyroid tumor cells exposed to both anti-
IL-4 and anti-IL-10 Abs, whereas the blockade of a single cytokine
had a lower effect (Fig. 6a). Importantly, a substantial number of
thyroid cancer cells underwent apoptosis on neutralization of IL-4 and
IL-10, indicating that these cytokines act as survival factors for
thyroid cancer (Fig. 6b). After IL-4 and IL-10 blockade, thyroid
cancer cell apoptosis was dramatically increased by the exposure to
Fig. 4. Production of T-helper cytokines in thy-
roid cancer. a, immunohistochemical analysis of
IFN-, IL-4, and IL-10 on paraffin-embedded con-
trol thyroid gland, PTC, FTC, and UTC sections
(red staining). b, immunostaining for cytokeratin,
IFN-, IL-4, and IL-10 in purified thyrocytes from
control and all histological variants of thyroid ep-
ithelial carcinoma. c, Western analysis of IFN-,
IL-10, and IL-4 in freshly purified cancer thyroid
cells. Recombinant human IFN-, IL-10, and IL-4
(20 ng/lane) were used as positive control (cyto-
kines). One representative of three independent ex-
periments, each using specimens or cells from dif-
ferent patients, is shown.
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chemotherapeutic drugs (Fig. 6c), confirming the hypothesis that
cytokine-mediated increase of Bcl-xL and Bcl-2 was responsible for
tumor cell resistance to chemotherapy. Similar data were obtained
with cells from PTC (data not shown). Although we could not analyze the
effect of neutralizing anti-IL-4 and anti-IL-10 Abs on apoptosis sensiti-
zation of UTC, down-regulation of Bcl-xL and Bcl-2 in PTC and FTC,
through the inhibition of T-helper cytokines, results in spontaneous death
of a considerable percentage of thyroid cancer cells and sensitization of
the survival tumor population to chemotherapy-induced cytotoxicity.
DISCUSSION
Cancer cell resistance to chemotherapy is a major concern in
clinical oncology, resulting in increased tumor growth and decreased
patient survival. The ability of cancer cells to resist the cytotoxic
effects of chemotherapy follows genetic alterations of the mechanisms
that control cell cycle checkpoints and apoptosis (33, 34). Because
cytotoxic drugs act by altering the balance between proapoptotic and
antiapoptotic signals, inappropriate activation of antiapoptotic genes
may result in the development of drug resistance (16).
We found that all of the histological variants of thyroid epithelial
cancer are weakly sensitive to chemotherapy and express high levels
of Bcl-2 and Bcl-xL. Moreover, exogenous expression of either Bcl-2
or Bcl-xL was sufficient to protect normal thyrocytes from chemo-
therapeutic drugs, whereas targeting the increased expression of an-
tiapoptotic proteins sensitized thyroid cancer cells to chemotherapy.
Bcl-2 and Bcl-xL are two antiapoptotic proto-oncogenes localized
to the outer mitochondrial membrane, which counteract the propaga-
tion of the apoptotic signals generated by a wide array of stimuli,
Fig. 5. IL-4 and IL-10 protect normal thyrocytes
from chemotherapy-induced apoptotic cell death. a,
cell death percentage of purified control thyrocytes
pretreated for 48 h with control medium (left), IL-4
(20 ng/ml; middle), or IL-10 (40 ng/ml; right) and
then cultured with cisplatinum, doxorubicin, and
taxol for 12 additional hours. b, immunoblot anal-
ysis of control thyrocytes cultured with IL-4 or
IL-10 for 48 h as in a or with IFN- (1000 IU/ml).
Fig. 6. Neutralizing Abs against IL-4 and IL-10
sensitize thyroid carcinoma cells to chemotherapy.
a, immunoblot analysis of FTC cells treated with
10 g/ml control IgG, anti-IL-4, anti-IL-10, or a
combination of anti-IL-4 and anti IL-10. Bcl-xL
transgenic hearts and HL-60 cells were used as
positive controls. Loading controls were performed
by detecting -actin on the same membrane. b,
kinetics of cell death performed on FTC cells ex-
posed to 10 g/ml anti-IL-4, anti-IL-10, or anti-IL-
4anti-IL-10. c, cell death percentage of purified
tumor thyroid cells pretreated with anti-IL-4 and
anti IL-10 simultaneously as in a and then cultured
with chemotherapeutic drugs for 12 additional
hours. Data are mean  SD of four independent
experiments.
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including chemotherapeutic agents (12, 15–17). Analysis of a consid-
erable number of cancer cell lines has shown a strong negative
correlation between basal Bcl-xL levels and sensitivity to chemother-
apeutic drugs (35). Furthermore, treatment of certain malignant cells
with antisense oligonucleotides or with plasmid constructs overex-
pressing antisense Bcl-2 or Bcl-xL decreased the rates of proliferation
and resistance to cytotoxic chemotherapeutic agents (18–21). Thus,
understanding the mechanisms underlying Bcl-2 and Bcl-xL overex-
pression may allow the development of effective therapeutic strategies.
Whereas in follicular lymphomas Bcl-2 overexpression results from
14;18 translocation, in most cases increased Bcl-2 and Bcl-xL expres-
sion in cancer is an indirect event (36). Several cytokines are known to
increase Bcl-2 or Bcl-xL expression. IL-3 increases Bcl-xL levels and
promotes survival and expansion of myeloid and pro-B cells (37). Sim-
ilarly, IL-5 and IL-15 activate Bcl-xL transcription and protect eosino-
phils and mast cells from apoptosis (38, 39), respectively, whereas IL-10
up-regulates Bcl-2 expression and promotes growth and survival of
germinal center B cells (40). Moreover, the increased TH2 profile of T
cells in chronic lymphocytic leukemia results in overproduction of IL-4,
which in turn induces Bcl-2 overexpression and increased survival of
malignant B cells (26). Thus, certain cytokines promote cancer cell
survival and expansion by stimulating the expression of antiapoptotic
genes.
Here, we have demonstrated that thyroid carcinoma cells produce
two antiapoptotic T-helper cytokines that alter sensitivity to cytotoxic
drugs. Expression of Bcl-2 and Bcl-xL is decreased after treatment
with neutralizing Abs against IL-4 and IL-10, which results in the
spontaneous death of a considerable percentage of cancer cells, indi-
cating that these cytokines act as survival factors for thyroid tumor
cells and may contribute to the progression of thyroid cancer. More-
over, neutralization of both IL-4 and IL-10 dramatically increased the
effectiveness of antineoplastic drugs on thyroid cancer cells. Although
we could not test the ability of blocking Abs against IL-4 and IL-10
to promote thyroid cancer cell death, we have shown that while
affecting TH1 antitumor activity by inducing immune deviation or
suppressing the immune response, TH2 and TH3 cytokines can di-
rectly act on target cancer cells by increasing their growth and
allowing malignant neoplasia to counteract cytotoxic therapies. This
may be significant in devising new therapeutic tools for sensitizing
thyroid cancer cells to chemotherapy.
The poor cytotoxic effect of chemotherapy on thyroid cancer has
directed most of the nonsurgical therapeutic efforts on radioiodine
therapy, which exploits the iodide uptake potential of thyroid follic-
ular cells to deliver iodine-131 to well-differentiated thyroid cancer
cells (2, 41). However, a significant number of patients do not respond
to radioiodine and have a very poor prognosis (42). The sensitization
of thyroid cancer cells to chemotherapy may dramatically improve the
survival rate of these patients, whereas targeting the ability of thyroid
cancer cells to exploit IL-4 and IL-10 as survival factors may provide
a powerful support to alternative treatments.
In conclusion, we provide evidence that IL-4 and IL-10 can directly
act on cancer cells by increasing the expression of antiapoptotic proteins,
thus promoting tumor cell progression and resistance to chemotherapy.
This is clearly observed in thyroid tumors in which IL-4 and IL-10 are
produced by epithelial cancer cells. These cytokines likely represent key
therapeutic targets for thyroid cancer treatment.
ACKNOWLEDGMENTS
We thank Dr. M. G. V. Latronico for suggestions and constructive criticism,
and Mr. A. Gorgone for expert technical help.
REFERENCES
1. Vini, L., and Harmer, C. Management of thyroid cancer. Lancet Oncol., 3: 407–414,
2002.
2. Gimm, O. Thyroid cancer. Cancer Lett., 163: 143–156, 2001.
3. Bartolazzi, A., and Gasbarri, A. Thyroid disease classification. Lancet, 356: 2010–
2011, 2000.
4. Hanna, N. N., McGrath, P. C., Sloan, D. A., and Kenady, D. E. Advances in the
pathogenesis and treatment of thyroid cancer. Curr. Opin. Oncol., 11: 42–47, 1999.
5. Haigh, P. I. Anaplastic thyroid carcinoma. Curr. Treat. Oncol., 1: 353–357, 2000.
6. Haigh, P. I., Ituarte, P. H., Wu, H. S., Treseler, P. A., Posner, M. D., Quivey, J. M.,
Duh, Q. Y., and Clark, O. H. Completely resected anaplastic thyroid carcinoma
combined with adjuvant chemotherapy and irradiation is associated with prolonged
survival. Cancer (Phila.), 91: 2335–2342, 2001.
7. Asakawa, H., Kobayashi, T., Komoike, Y., Maruyama, H., Nakano, Y., Tamaki, Y.,
Matsuzawa, Y., and Monden, M. Chemosensitivity of anaplastic thyroid carcinoma
and poorly differentiated thyroid carcinoma. Anticancer Res., 17: 2757–2762, 1997.
8. Sugawara, I., Arai, T., Yamashita, T., Yoshida, A., Masunaga, A., and Itoyama, S.
Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma
of the thyroid. Cancer Lett., 82: 185–188, 1994.
9. Sugawara, I., Masunaga, A., Itoyama, S., Sumizawa, T., Akiyama, S., and Yamashita,
T. Expression of multidrug resistance-associated protein (MRP) in thyroid cancers.
Cancer Lett., 95: 135–138, 1995.
10. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer
research. Science (Wash. DC), 287: 1969–1973, 2000.
11. Sellers, W. R., and Fisher, D. E. Apoptosis and cancer drug targeting. J. Clin. Invest.,
104: 1655–1661, 1999.
12. Huigsloot, M., Tijdens, I. B., Mulder, G. J., and van de Water, B. Differential regulation
of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary
adenocarcinoma (MTLn3) cells. J. Biol. Chem., 277: 35869–35879, 2002.
13. Ferrari, D., Stepczynska, A., Los, M., Wesselborg, S., and Schulze-Osthoff, K. Differen-
tial regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95-
and anticancer drug-induced apoptosis. J. Exp. Med., 188: 979–984, 1998.
14. Decaudin, D., Geley, S., Hirsch, T., Castedo, M., Marchetti, P., Macho, A., Kofler, R., and
Kroemer, G. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding
nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57: 62–67, 1997.
15. Hengartner, M. O. The biochemistry of apoptosis. Nature (Lond.), 407: 770–776, 2000.
16. Huang, Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 19:
6627–6631, 2000.
17. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P., and Stein, C. A. Bcl-xL in prostate
cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Cancer Res., 60: 6052–6060, 2000.
18. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller,
M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemo-
sensitizes human melanoma in SCID mice. Nat. Med., 4: 232–234, 1998.
19. Reed, J. C. Splicing and dicing apoptosis genes. Nat. Biotechnol., 17: 1064–1065, 1999.
20. Gautschi, O., Tschopp, S., Olie, R. A., Leech, S. H., Simoes-Wust, A. P., Ziegler, A.,
Baumann, B., Odermatt, B., Hall, J., Stahel, R. A., and Zangemeister-Wittke, U.
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors
of diverse histologic origins. J. Natl. Cancer Inst., 93: 463–471, 2001.
21. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., Simoes-Wust, A. P., Gautschi, O.,
Luedke, G. H., Natt, F., Haner, R., Martin, P., Hall, J., Nalin, C. M., and Stahel, R. A. A
novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression
efficiently induces apoptosis in tumor cells. Clin. Cancer Res., 6: 2547–2555, 2000.
22. Wang, S. H., Phelps, E., Utsugi, S., and Baker, J. R., Jr. Susceptibility of thyroid
cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 pro-
tein level. Thyroid, 11: 725–731, 2001.
23. Ahn, E. Y., Pan, G., Vickers, S. M., and McDonald, J. M. IFN- upregulates
apoptosis-related molecules and enhances Fas- mediated apoptosis in human cholan-
giocarcinoma. Int. J. Cancer, 100: 445–451, 2002.
24. Qin, J. Z., Zhang, C. L., Kamarashev, J., Dummer, R., Burg, G., and Dobbeling, U.
Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes
in cutaneous T-cell lymphoma cells. Blood, 98: 2778–2783, 2001.
25. Wurster, A. L., Rodgers, V. L., White, M. F., Rothstein, T. L., and Grusby, M. J.
Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-
dependent up-regulation of Bcl-xL. J. Biol. Chem., 277: 27169–27175, 2002.
26. Dancescu, M., Rubio-Trujillo, M., Biron, G., Bron, D., Delespesse, G., and Sarfati,
M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by
apoptosis and upregulates Bcl-2 expression. J. Exp. Med., 176: 1319–1326, 1992.
27. Weiner, H. L. Induction and mechanism of action of transforming growth factor--
secreting Th3 regulatory cells. Immunol. Rev., 182: 207–214, 2001.
28. Romagnani, S. The Th1/Th2 paradigm. Immunol. Today, 18: 263–266, 1997.
29. Abbas, A. K., Murphy, K. M., and Sher, A. Functional diversity of helper T
lymphocytes. Nature (Lond.), 383: 787–793, 1996.
30. Stassi, G., Di Liberto, D., Todaro, M., Zeuner, A., Ricci-Vitiani, L., Stoppacciaro, A.,
Ruco, L., Farina, F., Zummo, G., and De Maria, R. Control of target cell survival in
thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat.
Immunol., 1: 483–488, 2000.
31. Stassi, G., and De Maria, R. Autoimmune thyroid disease: new models of cell death
in autoimmunity. Nat. Rev. Immunol., 2: 195–204, 2002.
32. De Maria, R., Zeuner, A., Eramo, A., Domenichelli, C., Bonci, D., Grignani, F.,
Srinivasula, S. M., Alnemri, E. S., Testa, U., and Peschle, C. Negative regulation of
erythropoiesis by caspase-mediated cleavage of GATA-1. Nature (Lond.), 401:
489–493, 1999.
33. Vogelstein, B., and Kinzler, K. W. The multistep nature of cancer. Trends Genet., 9:
138–141, 1993.
6789
IL-4 AND IL-10 PRODUCTION IN THYROID CANCER
34. Shapiro, G. I., and Harper, J. W. Anticancer drug targets: cell cycle and checkpoint
control. J. Clin. Invest., 104: 1645–1653, 1999.
35. Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C., and Fornace,
A. J., Jr. An informatics approach identifying markers of chemosensitivity in human
cancer cell lines. Cancer Res., 60: 6101–6110, 2000.
36. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2
family and cell death. Blood, 88: 386–401, 1996.
37. Kieslinger, M., Woldman, I., Moriggl, R., Hofmann, J., Marine, J. C., Ihle, J. N.,
Beug, H., and Decker, T. Antiapoptotic activity of Stat5 required during terminal
stages of myeloid differentiation. Genes Dev., 14: 232–244, 2000.
38. Masuda, A., Matsuguchi, T., Yamaki, K., Hayakawa, T., and Yoshikai, Y. Interleu-
kin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expres-
sion. J. Biol. Chem., 276: 26107–26113, 2001.
39. Dibbert, B., Daigle, I., Braun, D., Schranz, C., Weber, M., Blaser, K., Zangemeister-
Wittke, U., Akbar, A. N., and Simon, H. U. Role for Bcl-xL in delayed eosinophil
apoptosis mediated by granulocyte-macrophage colony-stimulating factor and inter-
leukin-5. Blood, 92: 778–783, 1998.
40. Levy, Y., and Brouet, J. C. Interleukin-10 prevents spontaneous death of germinal
center B cells by induction of the bcl-2 protein. J. Clin. Invest., 93: 424 – 428,
1994.
41. Misaki, T., Iwata, M., Iida, Y., Kasagi, K., and Konishi, J. Chemo-radionuclide
therapy for thyroid cancer: initial experimental study with cultured cells. Ann. Nucl.
Med., 16: 403–408, 2002.
42. Wartofsky, L., Sherman, S. I., Gopal, J., Schlumberger, M., and Hay, I. D. The use
of radioactive iodine in patients with papillary and follicular thyroid cancer. J. Clin.
Endocrinol. Metab., 83: 4195–4203, 1998.
6790
IL-4 AND IL-10 PRODUCTION IN THYROID CANCER
